Chronic in vivo testing of the penn state infant ventricular assist device

William J. Weiss, Elizabeth L. Carney, J. Brian Clark, Rebecca Peterson, Timothy K. Cooper, Thomas P. Nifong, Christopher A. Siedlecki, Dennis Hicks, Bradley Doxtater, Branka Lukic, Eric Yeager, John Reibson, Joshua Cysyk, Gerson Rosenberg, William S. Pierce

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Penn State Infant Ventricular Assist Device (VAD) is a 12-14 ml stroke volume pneumatically actuated pump, with custom Björk-Shiley monostrut valves, developed under the National Heart, Lung, and Blood Institute Pediatric Circulatory Support program. In this report, we describe the seven most recent chronic animal studies of the Infant VAD in the juvenile ovine model, with a mean body weight of 23.5 ± 4.1 kg. The goal of 4-6 weeks survival was achieved in five of seven studies, with support duration ranging from 5 to 41 days; mean 26.1 days. Anticoagulation was accomplished using unfractionated heparin, and study animals were divided into two protocol groups: the first based on a target activated partial thromboplastin time of 1.5-2 times normal, and a second group using a target thromboelastography R-time of two times normal. The second group required significantly less heparin, which was verified by barely detectable heparin activity (anti-Xa). In both groups, there was no evidence of thromboembolism except in one animal with a chronic infection and fever. Device thrombi were minimal and were further reduced by introduction of the custom valve. These results are consistent with results of adult VAD testing in animals and are encouraging given the extremely low levels of anticoagulation in the second group.

Original languageEnglish (US)
Pages (from-to)65-72
Number of pages8
JournalASAIO Journal
Volume58
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Heart-Assist Devices
Animals
Heparin
Testing
Thrombelastography
National Heart, Lung, and Blood Institute (U.S.)
Pediatrics
Partial Thromboplastin Time
Thromboembolism
Thromboplastin
Stroke Volume
Sheep
Thrombosis
Blood
Fever
Body Weight
Pumps
Equipment and Supplies
Infection

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

Weiss, W. J., Carney, E. L., Clark, J. B., Peterson, R., Cooper, T. K., Nifong, T. P., ... Pierce, W. S. (2012). Chronic in vivo testing of the penn state infant ventricular assist device. ASAIO Journal, 58(1), 65-72. https://doi.org/10.1097/MAT.0b013e318239feb4
Weiss, William J. ; Carney, Elizabeth L. ; Clark, J. Brian ; Peterson, Rebecca ; Cooper, Timothy K. ; Nifong, Thomas P. ; Siedlecki, Christopher A. ; Hicks, Dennis ; Doxtater, Bradley ; Lukic, Branka ; Yeager, Eric ; Reibson, John ; Cysyk, Joshua ; Rosenberg, Gerson ; Pierce, William S. / Chronic in vivo testing of the penn state infant ventricular assist device. In: ASAIO Journal. 2012 ; Vol. 58, No. 1. pp. 65-72.
@article{4c2e778abcb74383a3b01bc6abf13ef0,
title = "Chronic in vivo testing of the penn state infant ventricular assist device",
abstract = "The Penn State Infant Ventricular Assist Device (VAD) is a 12-14 ml stroke volume pneumatically actuated pump, with custom Bj{\"o}rk-Shiley monostrut valves, developed under the National Heart, Lung, and Blood Institute Pediatric Circulatory Support program. In this report, we describe the seven most recent chronic animal studies of the Infant VAD in the juvenile ovine model, with a mean body weight of 23.5 ± 4.1 kg. The goal of 4-6 weeks survival was achieved in five of seven studies, with support duration ranging from 5 to 41 days; mean 26.1 days. Anticoagulation was accomplished using unfractionated heparin, and study animals were divided into two protocol groups: the first based on a target activated partial thromboplastin time of 1.5-2 times normal, and a second group using a target thromboelastography R-time of two times normal. The second group required significantly less heparin, which was verified by barely detectable heparin activity (anti-Xa). In both groups, there was no evidence of thromboembolism except in one animal with a chronic infection and fever. Device thrombi were minimal and were further reduced by introduction of the custom valve. These results are consistent with results of adult VAD testing in animals and are encouraging given the extremely low levels of anticoagulation in the second group.",
author = "Weiss, {William J.} and Carney, {Elizabeth L.} and Clark, {J. Brian} and Rebecca Peterson and Cooper, {Timothy K.} and Nifong, {Thomas P.} and Siedlecki, {Christopher A.} and Dennis Hicks and Bradley Doxtater and Branka Lukic and Eric Yeager and John Reibson and Joshua Cysyk and Gerson Rosenberg and Pierce, {William S.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1097/MAT.0b013e318239feb4",
language = "English (US)",
volume = "58",
pages = "65--72",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Weiss, WJ, Carney, EL, Clark, JB, Peterson, R, Cooper, TK, Nifong, TP, Siedlecki, CA, Hicks, D, Doxtater, B, Lukic, B, Yeager, E, Reibson, J, Cysyk, J, Rosenberg, G & Pierce, WS 2012, 'Chronic in vivo testing of the penn state infant ventricular assist device', ASAIO Journal, vol. 58, no. 1, pp. 65-72. https://doi.org/10.1097/MAT.0b013e318239feb4

Chronic in vivo testing of the penn state infant ventricular assist device. / Weiss, William J.; Carney, Elizabeth L.; Clark, J. Brian; Peterson, Rebecca; Cooper, Timothy K.; Nifong, Thomas P.; Siedlecki, Christopher A.; Hicks, Dennis; Doxtater, Bradley; Lukic, Branka; Yeager, Eric; Reibson, John; Cysyk, Joshua; Rosenberg, Gerson; Pierce, William S.

In: ASAIO Journal, Vol. 58, No. 1, 01.01.2012, p. 65-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic in vivo testing of the penn state infant ventricular assist device

AU - Weiss, William J.

AU - Carney, Elizabeth L.

AU - Clark, J. Brian

AU - Peterson, Rebecca

AU - Cooper, Timothy K.

AU - Nifong, Thomas P.

AU - Siedlecki, Christopher A.

AU - Hicks, Dennis

AU - Doxtater, Bradley

AU - Lukic, Branka

AU - Yeager, Eric

AU - Reibson, John

AU - Cysyk, Joshua

AU - Rosenberg, Gerson

AU - Pierce, William S.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The Penn State Infant Ventricular Assist Device (VAD) is a 12-14 ml stroke volume pneumatically actuated pump, with custom Björk-Shiley monostrut valves, developed under the National Heart, Lung, and Blood Institute Pediatric Circulatory Support program. In this report, we describe the seven most recent chronic animal studies of the Infant VAD in the juvenile ovine model, with a mean body weight of 23.5 ± 4.1 kg. The goal of 4-6 weeks survival was achieved in five of seven studies, with support duration ranging from 5 to 41 days; mean 26.1 days. Anticoagulation was accomplished using unfractionated heparin, and study animals were divided into two protocol groups: the first based on a target activated partial thromboplastin time of 1.5-2 times normal, and a second group using a target thromboelastography R-time of two times normal. The second group required significantly less heparin, which was verified by barely detectable heparin activity (anti-Xa). In both groups, there was no evidence of thromboembolism except in one animal with a chronic infection and fever. Device thrombi were minimal and were further reduced by introduction of the custom valve. These results are consistent with results of adult VAD testing in animals and are encouraging given the extremely low levels of anticoagulation in the second group.

AB - The Penn State Infant Ventricular Assist Device (VAD) is a 12-14 ml stroke volume pneumatically actuated pump, with custom Björk-Shiley monostrut valves, developed under the National Heart, Lung, and Blood Institute Pediatric Circulatory Support program. In this report, we describe the seven most recent chronic animal studies of the Infant VAD in the juvenile ovine model, with a mean body weight of 23.5 ± 4.1 kg. The goal of 4-6 weeks survival was achieved in five of seven studies, with support duration ranging from 5 to 41 days; mean 26.1 days. Anticoagulation was accomplished using unfractionated heparin, and study animals were divided into two protocol groups: the first based on a target activated partial thromboplastin time of 1.5-2 times normal, and a second group using a target thromboelastography R-time of two times normal. The second group required significantly less heparin, which was verified by barely detectable heparin activity (anti-Xa). In both groups, there was no evidence of thromboembolism except in one animal with a chronic infection and fever. Device thrombi were minimal and were further reduced by introduction of the custom valve. These results are consistent with results of adult VAD testing in animals and are encouraging given the extremely low levels of anticoagulation in the second group.

UR - http://www.scopus.com/inward/record.url?scp=84855342934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855342934&partnerID=8YFLogxK

U2 - 10.1097/MAT.0b013e318239feb4

DO - 10.1097/MAT.0b013e318239feb4

M3 - Article

C2 - 22157073

AN - SCOPUS:84855342934

VL - 58

SP - 65

EP - 72

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 1

ER -